Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Daily News

PCI via Ulnar Artery Equally as Safe and Effective as Transradial Approach

Michael O'Riordan

February 09, 2018

News Industry News

Oceanus 14 Pro, PTA balloon catheter receives CE Mark Approval

December 20, 2017

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

News Daily News

Older Age Tied to Higher Risk of Recurrent Cerebral Ischemia in PFO Closure Patients

Yael L. Maxwell

July 08, 2015

News Daily News

Endovascular Intervention Generally Safe in Elderly PAD Patients

June 20, 2011

Advertisement

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

PCI via Ulnar Artery Equally as Safe and Effective as Transradial Approach

Oceanus 14 Pro, PTA balloon catheter receives CE Mark Approval

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

Older Age Tied to Higher Risk of Recurrent Cerebral Ischemia in PFO Closure Patients

Endovascular Intervention Generally Safe in Elderly PAD Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content